Wave Life Sciences, Inc.(WVE)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Wave Life Sciences, Inc. (WVE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores WVE at 7.5/100 on a 32-signal composite quality model, placing it at rank #2,941 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (3.4) and balance sheet strength (3.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Wave Life Sciences, Inc. reports quarterly revenue of $2.3M, net income of $-69.4M, free cash flow of $-54.5M. Top institutional holders of WVE by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., BlackRock, GSK plc, based on the most recent SEC filings. WVE trades on the Nasdaq exchange and files with the SEC under CIK 1631574. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate WVE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Wave Life Sciences, Inc. directly from SEC EDGAR.